Singapore markets close in 6 hours 46 minutes

NeuBase Therapeutics, Inc. (NBSE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.1000-0.1600 (-4.91%)
At close: 1:00PM EST
3.1000 0.00 (0.00%)
After hours: 01:31PM EST
Currency in USD

Valuation measures

Market cap (intra-day) 5108.29M
Enterprise value 355.92M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)1.80
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7-2.48

Trading information

Stock price history

Beta (5Y monthly) -0.10
52-week change 3-59.58%
S&P500 52-week change 326.87%
52-week high 312.8900
52-week low 33.0300
50-day moving average 33.6806
200-day moving average 35.0372

Share statistics

Avg vol (3-month) 3145.35k
Avg vol (10-day) 3193.8k
Shares outstanding 532.72M
Implied shares outstanding 6N/A
Float 826.61M
% held by insiders 18.33%
% held by institutions 131.01%
Shares short (14 Nov 2021) 4606.85k
Short ratio (14 Nov 2021) 44.71
Short % of float (14 Nov 2021) 42.17%
Short % of shares outstanding (14 Nov 2021) 41.85%
Shares short (prior month 14 Oct 2021) 4593.35k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 303 Feb 2019
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 303 Feb 2019

Financial highlights

Fiscal year

Fiscal year ends 29 Sep 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-28.50%
Return on equity (ttm)-48.34%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -24.2M
Net income avi to common (ttm)-22.95M
Diluted EPS (ttm)-0.9220
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)58.84M
Total cash per share (mrq)1.8
Total debt (mrq)6.47M
Total debt/equity (mrq)10.74
Current ratio (mrq)19.18
Book value per share (mrq)1.84

Cash flow statement

Operating cash flow (ttm)-17M
Levered free cash flow (ttm)-13.52M